medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2022, Número 3

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2022; 33 (3)


Dislipidemias, hígado graso y enfermedad cardiovascular

Hidalgo I, Fonseca-Coronado S, Ceballos G, Meaney E, Nájera N

Idioma: Inglés [English version]
Referencias bibliográficas: 36
Paginas: 134-139
Archivo PDF: 217.30 Kb.


RESUMEN

La enfermedad del hígado graso no-alcohólico (NAFLD, por sus siglas en inglés) es el resultado de un estilo de vida poco saludable (que incluye una dieta hipercalórica y un estilo de vida sedentario) y enfermedades metabólicas como la obesidad, la resistencia a la insulina, la dislipidemia, la hipertensión y el síndrome metabólico. La acumulación de ácidos grasos libres (FFA, por sus siglas en inglés) y metabolitos lipídicos en los hepatocitos, provoca la alteración de la señalización celular desencadenada por la insulina y el desarrollo de resistencia a la insulina hepática, con el consecuente desarrollo de hiperglucemia e hiperinsulinemia. Además, el aumento de la lipogénesis y las anomalías en el metabolismo de los lípidos desencadenan una dislipidemia aterogénica con liberación de adipocinas que favorecen el desarrollo y la progresión de la NAFLD. Adicionalmente, las citocinas proinflamatorias se liberan en la circulación, lo que promueve inflamación crónica y susceptibilidad trombótica con daño microvascular sistémico, lo que lleva al desarrollo de enfermedad cardiovascular. Esta breve revisión aborda la asociación entre NAFLD, síndrome metabólico y enfermedad cardiovascular.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int. 2020; 14 (1): 8-23.

  2. Seghieri M, Christensen AS, Andersen A, Solini A, Knop FK, Vilsboll T. Future perspectives on GLP-1 receptor agonists and GLP-1/glucagon receptor co-agonists in the treatment of NAFLD. Front Endocrinol (Lausanne). 2018; 9: 649.

  3. Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur J Clin Invest. 2020; 50 (10): e13338.

  4. Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S et al. Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Int J Environ Res Public Health. 2019; 16 (17): 3104.

  5. Vranic L, Radovan A, Poropat G, Mikolasevic I, Milic S. Non-alcoholic fatty liver disease and COVID-19-two pandemics hitting at the same time. Medicina (Kaunas). 2021; 57 (10): 1057.

  6. Negro F. Natural history of NASH and HCC. Liver Int. 2020; 40 Suppl 1: 72-76.

  7. Augustin S, Graupera I, Caballeria J. Non-alcoholic fatty liver disease: A poorly known pandemic. Med Clin (Barc). 2017; 149 (12): 542-548.

  8. Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci. 2021; 271: 119220.

  9. Thomas DD, Corkey BE, Istfan NW, Apovian CM. Hyperinsulinemia: an early indicator of metabolic dysfunction. J Endocr Soc. 2019; 3 (9): 1727-1747.

  10. Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014; 6 (1): a009191.

  11. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007; 133 (2): 496-506.

  12. Edgerton DS, Lautz M, Scott M, Everett CA, Stettler KM, Neal DW et al. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest. 2006; 116 (2): 521-527.

  13. Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des. 2010; 16 (17): 1941-1951.

  14. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol. 2006; 101 (11): 2629-2640.

  15. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol. 2011; 17 (23): 2801-2811.

  16. Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci. 2017; 18 (8): 1649.

  17. Estrada-García T, Meaney A, López-Hernández D, Meaney E, Sánchez-Hernández O, Rodríguez-Arellano E et al. Hypertension and lipid triad are the most important attributable risks for myocardial infarction in a middle class urban Mexican population. Ann Nutr Metab. 2013; 63 (s1): 1-17.

  18. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363 (14): 1341-1350.

  19. Ma J, Hwang SJ, Pedley A, Massaro JM, Hoffmann U, Chung RT et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017; 66 (2): 390-397.

  20. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015; 47 (3): 181-190.

  21. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2014; 20 (7): 1724-1745.

  22. Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic fatty liver disease: an emerging driver of hypertension. Hypertension. 2020; 75 (2): 275-284.

  23. López-Suárez A, Guerrero JM, Elvira-González J, Beltrán-Robles M, Cañas-Hormigo F, Bascuñana-Quirell A. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol. 2011; 23 (11): 1011-1017.

  24. Jaruvongvanich V, Chenbhanich J, Sanguankeo A, Rattanawong P, Wijarnpreecha K, Upala S. Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017; 29 (9): e28-e35.

  25. Tana C, Tana M, Rossi S, Silingardi M, Schiavone C. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution. J Ultrasound. 2016; 19 (3): 183-189.

  26. Tana C, Schiavone C, Ticinesi A, Lauretani F, Nouvenne A, Dietrich CF et al. Hepatic artery resistive index as surrogate marker for fibrosis progression in NAFLD patients: A clinical perspective. Int J Immunopathol Pharmacol. 2018; 32: 2058738418781373.

  27. Francque S, Laleman W, Verbeke L, Van Steenkiste C, Casteleyn C, Kwanten W et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest. 2012; 92 (10): 1428-1439.

  28. Vonghia L, Magrone T, Verrijken A, Michielsen P, Van Gaal L, Jirillo E et al. Peripheral and hepatic vein cytokine levels in correlation with non-alcoholic fatty liver disease (NAFLD)-related metabolic, histological, and haemodynamic features. PLoS One. 2015; 10 (11): e0143380.

  29. Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine. 2012; 59 (2): 442-449.

  30. Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietilainen KH et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int. 2011; 31 (2): 176-183.

  31. Verrijken A, Francque S, Mertens I, Prawitt J, Caron S, Hubens G et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2014; 59 (1): 121-129.

  32. Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2013; 33 (10): 2454-2459.

  33. Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clin Liver Dis. 2018; 22 (1): 133-140.

  34. Serradilla Martín M, Oliver Guillén JR, Palomares Cano A, Ramia Ángel JM. Metabolic syndrome, non-alcoholic fatty liver disease and hepatocarcinoma. Rev Esp Enferm Dig. 2020; 112 (2): 133-138.

  35. Preuss HG, Kaats GR, Mrvichin N, Swaroop A, Bagchi D, Clouatre D et al. Examining the relationship between nonalcoholic fatty liver disease and the metabolic syndrome in nondiabetic subjects. J Am Coll Nutr. 2018; 37 (6): 457-465.

  36. Boursier J, Diehl AM. Nonalcoholic fatty liver disease and the gut microbiome. Clin Liver Dis. 2016; 20 (2): 263-275.




2020     |     www.medigraphic.com